GSK Plans U.S. Filing For Proprietary Adjuvant Pandemic Flu Vaccine In Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Vaccine also accepted for review in Europe.
You may also be interested in...
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.